Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB053914 plus Parsaclisib in Relapsed/Refractory DLBCL
NCT03688152Phase 1Completed
- Sponsor
- Incyte
- Start
- Dec 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INCB053914 in diffuse large B-cell lymphoma (DLBCL), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events up to 6 months. Started Dec 2018; status: completed.
02
Drugs
INCB053914
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03688152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03688152.